Try GOLD - Free
MedTech Disruption 2025: Startups Powering the Next Healthcare Leap
BioSpectrum Asia
|BioSpectrum Asia June 2025
As the MedTech industry strides into 2025 and beyond, innovations are transforming the way diagnosis, treatment, and patient engagement are delivered.
-
These advancements are centred around patient-centric care, the convergence of digital technologies, preventive health care, and personalised therapy – all aimed at improving outcomes and maximising patient satisfaction. The article will dive deep into six high-potential technology domains that are gaining global momentum and are set to transform the MedTech industry in the near future.
Technologies are expected to create a significant impact from 2025 to 2029, redefining how care is delivered to those in need. The technologies covered include: advanced neuromodulation, digital biomarkers, AI-based medical imaging, portable in-vitro diagnostics, intelligent tissue biopsy, and minimally invasive surgery. A new generation of startups are redefining modern healthcare fuelled by innovation and emerging technologies – and is poised to make a significant impact in 2025, with a focus on these six high-impact areas. From the long list of innovative startups, this article features a curated selection of top startups that meet at least one of the following criteria:
• Gained recent regulatory approval for their technology or solution
• Raised funding between 2023 and 2025,
• Are developing a first-in-class product
Advanced Neuromodulation
Advanced Neuromodulation is a minimally or non-invasive technology that delivers neuromodulation or neurostimulation to the spinal cord, peripheral, vagus, and pelvic nerves for a wide range of indicationsincluding autoimmune diseases, mental disorders, and chronic neuromuscular pain. The technology features miniaturised, low power consumption devices with wireless connectivity, setting it apart from traditional technologies requiring regular battery charging and revision surgeries to replace implants.
Top startups to watch in advanced neuromodulation space include:
This story is from the BioSpectrum Asia June 2025 edition of BioSpectrum Asia.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 9,500+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM BioSpectrum Asia
BioSpectrum Asia
Collaborative R&D: Partnerships shaping the future of biopharma
Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.
2 mins
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Quantum Computing: Future of diagnostics is being coded today
A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.
4 mins
BioSpectrum Asia Sep 2025
BioSpectrum Asia
First Pacific woman to serve as public health director in NZ
The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Hugel launches botulinum toxin Letybo in Malaysia
South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Australia designs smart wound monitor to improve chronic infection care
Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Revvity unveils innovative reagent technology to accelerate therapeutics development
US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B
Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education
HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI
Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.
1 min
BioSpectrum Asia Sep 2025
Listen
Translate
Change font size